• Hydroxychloroquine Sulfate: Evidence Scope

  2026-10-13

  APExBIO identifies Hydroxychloroquine Sulfate (SKU B4874; CAS 747-36-4) as a synthetic quinoline-derived sulfate salt offered for biomedical research. The available product information frames its conceptual scope around autophagy pathway modulation and toll-like receptor 7/9 signaling in autoimmune disease research, including systemic lupus erythematosus and rheumatoid arthritis. No matched research paper was provided, so mechanism, efficacy, comparative performance, and disease-model outcomes cannot be independently assessed here.

• Lanabecestat and the Limits of Partial BACE1 Inhibition

  2026-10-13

  Satir et al. reported that modest BACE inhibition reduced amyloid-beta secretion without detectable loss of synaptic transmission in cultured rat cortical neurons, whereas stronger inhibition was associated with reduced synaptic transmission. The findings support a cell-model distinction between partial and more extensive BACE1 inhibition, but they do not establish clinical efficacy, long-term safety, or cognitive benefit for Lanabecestat (AZD3293).

• FITC Goat Anti-Mouse IgG: Evidence Scope

  2026-10-12

  The APExBIO listing identifies K1201 as a FITC-conjugated, affinity-purified polyclonal goat secondary antibody intended for conceptual detection of mouse IgG primary antibodies. No matched research paper or independent performance evidence was available, so claims about specificity, sensitivity, signal amplification, and application suitability remain product-level descriptions rather than demonstrated findings.

• NSC 87877: Evidence, Scope, and Shp2 Signaling

  2026-10-12

  NSC 87877 is a supplier-described Shp1/Shp2 phosphatase inhibitor with reported activity in several signaling contexts. A separate preclinical stroke study implicates SHP2 in a tFUS–Nespas/miR-383-3p/NLRP3 pathway, but it does not establish that NSC 87877 was tested or that the compound has therapeutic value in stroke.

• ERAD-Hijacking for Transmembrane Protein Degradation

  2026-10-11

  The 2026 Cell study introduces ERAD-engaging chimeras (ERADECs), a targeted protein degradation strategy that redirects transmembrane proteins toward endoplasmic-reticulum-associated degradation. Its strongest evidence centers on SYVN1-dependent degradation of PD-L1, with reported sub-nanomolar activity and tumor-suppression effects in vivo, while also identifying desonide as a chemical warhead for ERAD engagement.

• T0070907 as a PPARγ Antagonist: Evidence and Limits

  2026-10-10

  T0070907 is a covalent PPARγ antagonist used as a mechanistic research probe in adipogenesis, nuclear-receptor signaling, inflammation, and cancer biology. This overview separates supplier-reported pharmacology from findings in a 2025 berberine–atherosclerosis study, explains how PPARγ/RXRα heterodimer modulation may be interpreted conceptually, and outlines important limits involving assay context, species, receptor isoforms, off-target effects, and the absence of clinical evidence.

• 4-Hydroxytamoxifen Product Overview

  2026-10-09

  4-Hydroxytamoxifen (SKU B6167) is described by APExBIO as an estrogen receptor modulator for research contexts including breast cancer research, prostate cancer research, apoptosis assays, and cardiac myocyte calcium handling studies. No matched paper evidence was provided, so efficacy, mechanism, safety, and reproducibility cannot be independently assessed here.

• Cannabis Terpenes, A2A Signaling, and Neuropathic Pain

  2026-10-09

  Schwarz et al. identify adenosine A2A receptor signaling as a key mediator of antinociception produced by five Cannabis sativa terpenes in mouse models of neuropathic and inflammatory pain. The study combines behavioral pharmacology, receptor perturbation, cellular assays, and modeling to support a non-cannabinoid mechanism, while its findings remain preclinical and model-dependent.

• Caspase-8 Activity in Apoptosis Research

  2026-10-08

  Caspase-8 is a cysteine-dependent aspartate-directed protease positioned at the intersection of apoptosis, inflammatory cell death and pyroptosis. This overview examines how an IETD-based fluorometric assay can support caspase activity measurement, what a 2024 hyperthermia–cisplatin study reported about caspase-8 accumulation, and why substrate cleavage alone cannot establish a complete cell-death mechanism.

• Nascent Cone Precursors and Retinoblastoma Origin

  2026-10-08

  A 2026 Cell Death and Disease study uses RB1-deficient human retinal organoids and single-cell analysis to identify ATOH7+/RXRγ+ nascent cone precursors as the earliest cellular origin of human retinoblastoma. The work separates the effects of complete and monoallelic RB1 loss, providing a developmental framework for interpreting tumor initiation and evaluating future retinoblastoma therapies.

• Cimetidine in BBB and Cancer Research Context

  2026-10-07

  Cimetidine is a histamine-2 receptor antagonist studied across pharmacology and cancer research, but the supplied 2025 BBB paper evaluates a screening platform rather than cimetidine itself. This overview separates documented platform findings from hypotheses about Cimetidine, H2 receptor signaling, gastrointestinal cancer, and brain distribution.

• LY2886721 and BACE1 Inhibition: Evidence Overview

  2026-10-07

  This overview examines LY2886721 as a BACE inhibitor in Alzheimer’s disease research, distinguishing supplier-reported potency and animal biomarker findings from peer-reviewed evidence on amyloid beta reduction and synaptic transmission. It compares biochemical, cellular, animal, and functional evidence while emphasizing model limitations, uncertain clinical translation, and the difference between target engagement and demonstrated therapeutic benefit.

• Transcription Termination Limits DNA Damage After WEE1

  2026-10-06

  Landsverk and colleagues show that transcription termination acts as a genome-protective mechanism during the replication stress caused by WEE1 inhibition. Their genetic and pharmacological evidence links transcriptional read-through with S-phase DNA damage and reduced cancer-cell survival, identifying termination control as an important modifier of WEE1-inhibitor response.

• FPH1 (BRD-6125): Evidence and Research Context

  2026-10-06

  FPH1, also known as BRD-6125, is cataloged as a small-molecule enhancer of hepatocyte proliferation and function. This overview separates supplier-reported findings from peer-reviewed evidence, outlines conceptual applications in hepatocyte assays and iPSC-derived models, and explains why the available evidence remains insufficient for strong claims about mechanism, donor independence, long-term phenotype, or clinical translation.

• Human iPSC Intestinal Organoids for Pharmacokinetics

  2026-10-05

  Saito and colleagues developed a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be maintained, cryopreserved, and converted into intestinal epithelial monolayers containing metabolically relevant enterocyte-like cells, supporting their use as a human in vitro model for absorption and drug-metabolism research.

7917 records 1/528 page Next 12345 下5页 Last page